Search

Your search keyword '"Boer J. M."' showing total 180 results
Start Over Author "Boer J. M."
180 results on '"Boer J. M."'

1. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

Author

Boer, J M, van der Veer, A, Rizopoulos, D, Fiocco, M, Sonneveld, E, de Groot-Kruseman, H A, Kuiper, R P, Hoogerbrugge, P, Horstmann, M, Zaliova, M, Palmi, C, Trka, J, Fronkova, E, Emerenciano, M, do Socorro Pombo-de-Oliveira, M, Mlynarski, W, Szczepanski, T, Nebral, K, Attarbaschi, A, Venn, N, Sutton, R, Schwab, C J, Enshaei, A, Vora, A, Stanulla, M, Schrappe, M, Cazzaniga, G, Conter, V, Zimmermann, M, Moorman, A V, Pieters, R, and den Boer, M L

Published
2016
Full Text
View/download PDF

2. Genomics of human longevity

Author

Slagboom, P. E., Beekman, M., Passtoors, W. M., Deelen, J., Vaarhorst, A. A. M., Boer, J. M., van den Akker, E. B., van Heemst, D., de Craen, A. J. M., Maier, A. B., Rozing, M., Mooijaart, S. P., Heijmans, B. T., and Westendorp, R. G. J.

Published
2011

3. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Author

Pennesi, E, Michels, N, Brivio, E, van der Velden, V, Jiang, Y, Thano, A, Ammerlaan, A, Boer, J, Beverloo, H, Sleight, B, Chen, Y, Vormoor-Burger, B, Rives, S, Bielorai, B, Rossig, C, Petit, A, Rizzari, C, Engstler, G, Stary, J, Bautista Sirvent, F, Chen-Santel, C, Bruno, B, Bertrand, Y, Rialland, F, Plat, G, Reinhardt, D, Vinti, L, Von Stackelberg, A, Locatelli, F, Zwaan, C, Pennesi E., Michels N., Brivio E., van der Velden V. H. J., Jiang Y., Thano A., Ammerlaan A. J. C., Boer J. M., Beverloo H. B., Sleight B., Chen Y., Vormoor-Burger B., Rives S., Bielorai B., Rossig C., Petit A., Rizzari C., Engstler G., Stary J., Bautista Sirvent F. J., Chen-Santel C., Bruno B., Bertrand Y., Rialland F., Plat G., Reinhardt D., Vinti L., Von Stackelberg A., Locatelli F., Zwaan C. M., Pennesi, E, Michels, N, Brivio, E, van der Velden, V, Jiang, Y, Thano, A, Ammerlaan, A, Boer, J, Beverloo, H, Sleight, B, Chen, Y, Vormoor-Burger, B, Rives, S, Bielorai, B, Rossig, C, Petit, A, Rizzari, C, Engstler, G, Stary, J, Bautista Sirvent, F, Chen-Santel, C, Bruno, B, Bertrand, Y, Rialland, F, Plat, G, Reinhardt, D, Vinti, L, Von Stackelberg, A, Locatelli, F, Zwaan, C, Pennesi E., Michels N., Brivio E., van der Velden V. H. J., Jiang Y., Thano A., Ammerlaan A. J. C., Boer J. M., Beverloo H. B., Sleight B., Chen Y., Vormoor-Burger B., Rives S., Bielorai B., Rossig C., Petit A., Rizzari C., Engstler G., Stary J., Bautista Sirvent F. J., Chen-Santel C., Bruno B., Bertrand Y., Rialland F., Plat G., Reinhardt D., Vinti L., Von Stackelberg A., Locatelli F., and Zwaan C. M.

Abstract

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1–18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using a single-stage design, with an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% as expected, 25 patients needed to be recruited to achieve 80% power at 0.05 significance level. Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated ORR was 81.5% (95%CI: 61.9–93.7%), and 81.8% (18/22) of the responding subjects were minimal residual disease (MRD) negative. The study met its primary endpoint. Median follow up of survivors was 16 months (IQR: 14.49–20.07). One year Event Free Survival was 36.7% (95% CI: 22.2–60.4%), and Overall Survival was 55.1% (95% CI: 39.1−77.7%). Eighteen patients received consolidation (with HSCT and/or CAR T-cells therapy). Sinusoidal obstructive syndrome (SOS) occurred in seven patients. MRD negativity seemed correlated to calicheamicin sensitivity in vitro, but not to CD22 surface expression, saturation, or internalization. InO was effective in this population. The most relevant risk was the occurrence of SOS, particularly when InO treatment was followed by HSCT.

Published
2022

4. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol

Author

Stutterheim, J., de Lorenzo, P., van der Sluis, I. M., Alten, J., Ancliffe, P., Attarbaschi, A., Aversa, L., Boer, J. M., Biondi, A., Brethon, B., Diaz, P., Cazzaniga, G., Escherich, G., Ferster, A., Kotecha, R. S., Lausen, B., Leung, A. W., Locatelli, Franco, Silverman, L., Stary, J., Szczepanski, T., van der Velden, V. H. J., Vora, A., Zuna, J., Schrappe, M., Valsecchi, M. G., Pieters, R., Locatelli F. (ORCID:0000-0002-7976-3654), Stutterheim, J., de Lorenzo, P., van der Sluis, I. M., Alten, J., Ancliffe, P., Attarbaschi, A., Aversa, L., Boer, J. M., Biondi, A., Brethon, B., Diaz, P., Cazzaniga, G., Escherich, G., Ferster, A., Kotecha, R. S., Lausen, B., Leung, A. W., Locatelli, Franco, Silverman, L., Stary, J., Szczepanski, T., van der Velden, V. H. J., Vora, A., Zuna, J., Schrappe, M., Valsecchi, M. G., Pieters, R., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Background: The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. Methods: Univariate analysis on prognostic factors (age, white blood cell count at diagnosis, prednisolone response and CD10 expression) was performed on KMT2A-germline infants in complete remission at the end of induction (EOI; n = 163). Bone marrow minimal residual disease (MRD) was measured in 73 patients by real-time quantitative polymerase chain reaction at various time points (EOI, n = 68; end of consolidation, n = 56; and before OCTADAD, n = 57). MRD results were classified as negative, intermediate (<5∗10−4), and high (≥5∗10−4). Results: The 6-year event-free and overall survival was 73.9% (standard error [SE] = 3.6) and 87.2% (SE = 2.7). Relapses occurred early, within 36 months from diagnosis in 28 of 31 (90%) infants. Treatment-related mortality was 3.6%. Age <6 months was a favourable prognostic factor with a 6-year disease-free survival (DFS) of 91% (SE = 9.0) compared with 71.7% (SE = 4.2) in infants >6 months of age (P = 0.04). Patients with high EOI MRD ≥5 × 10−4 had a worse outcome (6-year DFS 61.4% [SE = 12.4], n = 16), compared with patients with undetectable EOI MRD (6-year DFS 87.9% [SE = 6.6], n = 28) or intermediate EOI MRD <5 × 10−4 (6-year DFS 76.4% [SE = 11.3], n = 24; P = 0.02). Conclusion: We conclude that young age at diagnosis and low EOI MRD seem favourable prognostic factors in infants with KMT2A-germline ALL and should be considered for risk stratification in future clinical trials.

Published
2022

5. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Author

Pennesi, E., Michels, N., Brivio, E., van der Velden, V. H. J., Jiang, Y., Thano, A., Ammerlaan, A. J. C., Boer, J. M., Beverloo, H. B., Sleight, B., Chen, Y., Vormoor-Burger, B., Rives, S., Bielorai, B., Rossig, C., Petit, A., Rizzari, C., Engstler, G., Stary, J., Bautista Sirvent, F. J., Chen-Santel, C., Bruno, B., Bertrand, Y., Rialland, F., Plat, G., Reinhardt, D., Vinti, L., Von Stackelberg, A., Locatelli, Franco, Zwaan, C. M., Locatelli F. (ORCID:0000-0002-7976-3654), Pennesi, E., Michels, N., Brivio, E., van der Velden, V. H. J., Jiang, Y., Thano, A., Ammerlaan, A. J. C., Boer, J. M., Beverloo, H. B., Sleight, B., Chen, Y., Vormoor-Burger, B., Rives, S., Bielorai, B., Rossig, C., Petit, A., Rizzari, C., Engstler, G., Stary, J., Bautista Sirvent, F. J., Chen-Santel, C., Bruno, B., Bertrand, Y., Rialland, F., Plat, G., Reinhardt, D., Vinti, L., Von Stackelberg, A., Locatelli, Franco, Zwaan, C. M., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1–18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using a single-stage design, with an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% as expected, 25 patients needed to be recruited to achieve 80% power at 0.05 significance level. Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated ORR was 81.5% (95%CI: 61.9–93.7%), and 81.8% (18/22) of the responding subjects were minimal residual disease (MRD) negative. The study met its primary endpoint. Median follow up of survivors was 16 months (IQR: 14.49–20.07). One year Event Free Survival was 36.7% (95% CI: 22.2–60.4%), and Overall Survival was 55.1% (95% CI: 39.1−77.7%). Eighteen patients received consolidation (with HSCT and/or CAR T-cells therapy). Sinusoidal obstructive syndrome (SOS) occurred in seven patients. MRD negativity seemed correlated to calicheamicin sensitivity in vitro, but not to CD22 surface expression, saturation, or internalization. InO was effective in this population. The most relevant risk was the occurrence of SOS, particularly when InO treatment was followed by HSCT.

Published
2022

6. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol

Author

Stutterheim, J, de Lorenzo, P, van der Sluin, I, Alten, J, Ancliffe, P, Attarbaschi, A, Aversa, L, Boer, J, Biondi, A, Brethon, B, Diaz, P, Cazzaniga, G, Escherich, G, Ferster, A, Kotecha, R, Lausen, B, Leung, A, Locatelli, F, Silverman, L, Stary, J, Szczepanski, T, van der Velden, V, Vora, A, Zuna, J, Schrappe, M, Valsecchi, M, Pieters, R, Stutterheim J., de Lorenzo P., van der Sluin I. M., Alten J., Ancliffe P., Attarbaschi A., Aversa L., Boer J. M., Biondi A., Brethon B., Diaz P., Cazzaniga G., Escherich G., Ferster A., Kotecha R. S., Lausen B., Leung A. W., Locatelli F., Silverman L., Stary J., Szczepanski T., van der Velden V. H. J., Vora A., Zuna J., Schrappe M., Valsecchi M. G., Pieters R., Stutterheim, J, de Lorenzo, P, van der Sluin, I, Alten, J, Ancliffe, P, Attarbaschi, A, Aversa, L, Boer, J, Biondi, A, Brethon, B, Diaz, P, Cazzaniga, G, Escherich, G, Ferster, A, Kotecha, R, Lausen, B, Leung, A, Locatelli, F, Silverman, L, Stary, J, Szczepanski, T, van der Velden, V, Vora, A, Zuna, J, Schrappe, M, Valsecchi, M, Pieters, R, Stutterheim J., de Lorenzo P., van der Sluin I. M., Alten J., Ancliffe P., Attarbaschi A., Aversa L., Boer J. M., Biondi A., Brethon B., Diaz P., Cazzaniga G., Escherich G., Ferster A., Kotecha R. S., Lausen B., Leung A. W., Locatelli F., Silverman L., Stary J., Szczepanski T., van der Velden V. H. J., Vora A., Zuna J., Schrappe M., Valsecchi M. G., and Pieters R.

Abstract

Background: The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. Methods: Univariate analysis on prognostic factors (age, white blood cell count at diagnosis, prednisolone response and CD10 expression) was performed on KMT2A-germline infants in complete remission at the end of induction (EOI; n = 163). Bone marrow minimal residual disease (MRD) was measured in 73 patients by real-time quantitative polymerase chain reaction at various time points (EOI, n = 68; end of consolidation, n = 56; and before OCTADAD, n = 57). MRD results were classified as negative, intermediate (<5∗10−4), and high (≥5∗10−4). Results: The 6-year event-free and overall survival was 73.9% (standard error [SE] = 3.6) and 87.2% (SE = 2.7). Relapses occurred early, within 36 months from diagnosis in 28 of 31 (90%) infants. Treatment-related mortality was 3.6%. Age <6 months was a favourable prognostic factor with a 6-year disease-free survival (DFS) of 91% (SE = 9.0) compared with 71.7% (SE = 4.2) in infants >6 months of age (P = 0.04). Patients with high EOI MRD ≥5 × 10−4 had a worse outcome (6-year DFS 61.4% [SE = 12.4], n = 16), compared with patients with undetectable EOI MRD (6-year DFS 87.9% [SE = 6.6], n = 28) or intermediate EOI MRD <5 × 10−4 (6-year DFS 76.4% [SE = 11.3], n = 24; P = 0.02). Conclusion: We conclude that young age at diagnosis and low EOI MRD seem favourable prognostic factors in infants with KMT2A-germline ALL and should be considered for risk stratification in future clinical trials.

Published
2022

9. Milk intake and incident stroke and CHD in populations of European descent: a Mendelian randomisation study.

Author

Vissers, L. E. T., Sluijs, I., Burgess, S., Forouhi, N. G., Freisling, H., Imamura, F., Nilsson, T. K., Renström, F., Weiderpass, E., Aleksandrova, K., Dahm, C. C., Perez-Cornago, A., Schulze, M. B., Tong, T. Y. N., Aune, D., Bonet, C., Boer, J. M. A., Boeing, H., Chirlaque, M. D., and Conchi, M. I.

Subjects
CORONARY heart disease risk factors, STROKE risk factors, CARDIOVASCULAR diseases risk factors, RELATIVE medical risk, GENETICS, CONFIDENCE intervals, MILK, ALLELES, DAIRY products, RISK assessment, DESCRIPTIVE statistics, ODDS ratio, DATA analysis software, PROPORTIONAL hazards models
Abstract

Higher milk intake has been associated with a lower stroke risk, but not with risk of CHD. Residual confounding or reverse causation cannot be excluded. Therefore, we estimated the causal association of milk consumption with stroke and CHD risk through instrumental variable (IV) and gene-outcome analyses. IV analysis included 29 328 participants (4611 stroke; 9828 CHD) of the European Prospective Investigation into Cancer and Nutrition (EPIC)-CVD (eight European countries) and European Prospective Investigation into Cancer and Nutrition-Netherlands (EPIC-NL) case-cohort studies. rs4988235, a lactase persistence (LP) SNP which enables digestion of lactose in adulthood was used as genetic instrument. Intake of milk was first regressed on rs4988235 in a linear regression model. Next, associations of genetically predicted milk consumption with stroke and CHD were estimated using Prentice-weighted Cox regression. Gene-outcome analysis included 777 024 participants (50 804 cases) from MEGASTROKE (including EPIC-CVD), UK Biobank and EPIC-NL for stroke, and 483 966 participants (61 612 cases) from CARDIoGRAM, UK Biobank, EPIC-CVD and EPIC-NL for CHD. In IV analyses, each additional LP allele was associated with a higher intake of milk in EPIC-CVD (β = 13·7 g/d; 95 % CI 8·4, 19·1) and EPIC-NL (36·8 g/d; 95 % CI 20·0, 53·5). Genetically predicted milk intake was not associated with stroke (HR per 25 g/d 1·05; 95 % CI 0·94, 1·16) or CHD (1·02; 95 % CI 0·96, 1·08). In gene-outcome analyses, there was no association of rs4988235 with risk of stroke (OR 1·02; 95 % CI 0·99, 1·05) or CHD (OR 0·99; 95 % CI 0·95, 1·03). Current Mendelian randomisation analysis does not provide evidence for a causal inverse relationship between milk consumption and stroke or CHD risk. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

10. Milk intake and incident stroke and CHD in populations of European descent: a Mendelian randomisation study

Author

Vissers, L. E. T., primary, Sluijs, I., additional, Burgess, S., additional, Forouhi, N. G., additional, Freisling, H., additional, Imamura, F., additional, Nilsson, T. K., additional, Renström, F., additional, Weiderpass, E., additional, Aleksandrova, K., additional, Dahm, C. C., additional, Perez-Cornago, A., additional, Schulze, M. B., additional, Tong, T. Y. N., additional, Aune, D., additional, Bonet, C., additional, Boer, J. M. A., additional, Boeing, H., additional, Chirlaque, M. D., additional, Conchi, M. I., additional, Imaz, L., additional, Jäger, S., additional, Krogh, V., additional, Kyrø, C., additional, Masala, G., additional, Melander, O., additional, Overvad, K., additional, Panico, S., additional, Sánches, M. J., additional, Sonestedt, E., additional, Tjønneland, A., additional, Tzoulaki, I., additional, Verschuren, W. M. M., additional, Riboli, E., additional, Wareham, N. J., additional, Danesh, J., additional, Butterworth, A. S., additional, and van der Schouw, Y. T., additional

Published
2021
Full Text
View/download PDF

12. Dietary fibre intake and ischaemic heart disease mortality: the European Prospective Investigation into Cancer and Nutrition-Heart study

Author

Crowe, F L, Key, T J, Appleby, P N, Overvad, K, Schmidt, E B, Egeberg, R, Tjønneland, A, Kaaks, R, Teucher, B, Boeing, H, Weikert, C, Trichopoulou, A, Ouranos, V, Valanou, E, Masala, G, Sieri, S, Panico, S, Tumino, R, Matullo, G, Bueno-de-Mesquita, H B, Boer, J M A, Beulens, J W J, van der Schouw, Y T, Quirós, J R, Buckland, G, Sánchez, M-J, Dorronsoro, M, Huerta, J M, Moreno-Iribas, C, Hedblad, B, Jansson, J H, Wennberg, P, Khaw, K-T, Wareham, N, Ferrari, P, Illner, A-K, Chuang, S-C, Norat, T, Danesh, J, and Riboli, E

Published
2012
Full Text
View/download PDF

17. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Author

Hirabayashi, S, Butler, E, Ohki, K, Kiyokawa, N, Bergmann, A, Moricke, A, Boer, J, Cave, H, Cazzaniga, G, Yeoh, A, Sanada, M, Imamura, T, Inaba, H, Mullighan, C, Loh, M, Noren-Nystrom, U, Pastorczak, A, Shih, L, Zaliova, M, Pui, C, Haas, O, Harrison, C, Moorman, A, Manabe, A, Hirabayashi S., Butler E. R., Ohki K., Kiyokawa N., Bergmann A. K., Moricke A., Boer J. M., Cave H., Cazzaniga G., Yeoh A. E. J., Sanada M., Imamura T., Inaba H., Mullighan C., Loh M. L., Noren-Nystrom U., Pastorczak A., Shih L. -Y., Zaliova M., Pui C. -H., Haas O. A., Harrison C. J., Moorman A. V., Manabe A., Hirabayashi, S, Butler, E, Ohki, K, Kiyokawa, N, Bergmann, A, Moricke, A, Boer, J, Cave, H, Cazzaniga, G, Yeoh, A, Sanada, M, Imamura, T, Inaba, H, Mullighan, C, Loh, M, Noren-Nystrom, U, Pastorczak, A, Shih, L, Zaliova, M, Pui, C, Haas, O, Harrison, C, Moorman, A, Manabe, A, Hirabayashi S., Butler E. R., Ohki K., Kiyokawa N., Bergmann A. K., Moricke A., Boer J. M., Cave H., Cazzaniga G., Yeoh A. E. J., Sanada M., Imamura T., Inaba H., Mullighan C., Loh M. L., Noren-Nystrom U., Pastorczak A., Shih L. -Y., Zaliova M., Pui C. -H., Haas O. A., Harrison C. J., Moorman A. V., and Manabe A.

Published
2021

18. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

Author

Boer, J, Valsecchi, M, Hormann, F, Antic, Z, Zaliova, M, Schwab, C, Cazzaniga, G, Arfeuille, C, Cave, H, Attarbaschi, A, Strehl, S, Escherich, G, Imamura, T, Ohki, K, Gruber, T, Sutton, R, Pastorczak, A, Lammens, T, Lambert, F, Li, C, Carrillo de Santa Pau, E, Hoffmann, S, Moricke, A, Harrison, C, Den Boer, M, De Lorenzo, P, Stam, R, Bergmann, A, Pieters, R, Boer J. M., Valsecchi M. G., Hormann F. M., Antic Z., Zaliova M., Schwab C., Cazzaniga G., Arfeuille C., Cave H., Attarbaschi A., Strehl S., Escherich G., Imamura T., Ohki K., Gruber T. A., Sutton R., Pastorczak A., Lammens T., Lambert F., Li C. K., Carrillo de Santa Pau E., Hoffmann S., Moricke A., Harrison C. J., Den Boer M. L., De Lorenzo P., Stam R. W., Bergmann A. K., Pieters R., Boer, J, Valsecchi, M, Hormann, F, Antic, Z, Zaliova, M, Schwab, C, Cazzaniga, G, Arfeuille, C, Cave, H, Attarbaschi, A, Strehl, S, Escherich, G, Imamura, T, Ohki, K, Gruber, T, Sutton, R, Pastorczak, A, Lammens, T, Lambert, F, Li, C, Carrillo de Santa Pau, E, Hoffmann, S, Moricke, A, Harrison, C, Den Boer, M, De Lorenzo, P, Stam, R, Bergmann, A, Pieters, R, Boer J. M., Valsecchi M. G., Hormann F. M., Antic Z., Zaliova M., Schwab C., Cazzaniga G., Arfeuille C., Cave H., Attarbaschi A., Strehl S., Escherich G., Imamura T., Ohki K., Gruber T. A., Sutton R., Pastorczak A., Lammens T., Lambert F., Li C. K., Carrillo de Santa Pau E., Hoffmann S., Moricke A., Harrison C. J., Den Boer M. L., De Lorenzo P., Stam R. W., Bergmann A. K., and Pieters R.

Published
2021

19. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

Author

den Boer, M, Cario, G, Moorman, A, Boer, J, de Groot-Kruseman, H, Fiocco, M, Escherich, G, Imamura, T, Yeoh, A, Sutton, R, Dalla-Pozza, L, Kiyokawa, N, Schrappe, M, Roberts, K, Mullighan, C, Hunger, S, Vora, A, Attarbaschi, A, Zaliova, M, Elitzur, S, Cazzaniga, G, Biondi, A, Loh, M, Pieters, R, den Boer M. L., Cario G., Moorman A. V., Boer J. M., de Groot-Kruseman H. A., Fiocco M., Escherich G., Imamura T., Yeoh A., Sutton R., Dalla-Pozza L., Kiyokawa N., Schrappe M., Roberts K. G., Mullighan C. G., Hunger S. P., Vora A., Attarbaschi A., Zaliova M., Elitzur S., Cazzaniga G., Biondi A., Loh M. L., Pieters R., den Boer, M, Cario, G, Moorman, A, Boer, J, de Groot-Kruseman, H, Fiocco, M, Escherich, G, Imamura, T, Yeoh, A, Sutton, R, Dalla-Pozza, L, Kiyokawa, N, Schrappe, M, Roberts, K, Mullighan, C, Hunger, S, Vora, A, Attarbaschi, A, Zaliova, M, Elitzur, S, Cazzaniga, G, Biondi, A, Loh, M, Pieters, R, den Boer M. L., Cario G., Moorman A. V., Boer J. M., de Groot-Kruseman H. A., Fiocco M., Escherich G., Imamura T., Yeoh A., Sutton R., Dalla-Pozza L., Kiyokawa N., Schrappe M., Roberts K. G., Mullighan C. G., Hunger S. P., Vora A., Attarbaschi A., Zaliova M., Elitzur S., Cazzaniga G., Biondi A., Loh M. L., and Pieters R.

Abstract

Background: ABL-class fusion genes other than BCR–ABL1 have been identified in approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemic cells carrying ABL-class fusions can be targeted successfully by tyrosine-kinase inhibitors. We aimed to establish the baseline characteristics and outcomes of paediatric patients with ABL-class fusion B-cell acute lymphocytic leukaemia in the pre-tyrosine-kinase inhibitor era. Methods: This multicentre, retrospective, cohort study included paediatric patients (aged 1–18 years) with newly diagnosed ABL-class fusion (ABL1 fusion-positive, ABL2 fusion-positive, CSF1R fusion-positive, and PDGFRB fusion-positive) B-cell acute lymphocytic leukaemia enrolled in clinical trials of multidrug chemotherapy done between Oct 3, 2000, and Aug 28, 2018, in which tyrosine-kinase inhibitors had not been given as a first-line treatment. Patients from 14 European, North American, and Asia-Pacific study groups of the Ponte di Legno group were included. No patients were excluded, and patients were followed up by individual study groups. Through the Ponte di Legno group, we collected data on the baseline characteristics of patients, including IKZF1, PAX5, and CDKN2A/B deletion status, and whether haematopoietic stem cell transplantation (HSCT) had been done, as well as treatment outcomes, including complete remission, no response, relapse, early death, and treatment-related mortality, response to prednisone, and minimal residual disease (MRD) at end of induction therapy. 5-year event-free survival and 5-year overall survival were estimated by use of Kaplan-Meier methods, and the 5-year cumulative incidence of relapse was calculated by use of a competing risk model. Findings: We identified 122 paediatric patients with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukaemia (77 from European study groups, 25 from North American study groups, and 20 from Asia-Pacific study groups). 64 (52

Published
2021

22. Working group on epidemiology & prevention of the european society of cardiology: Proceedings of meeting held at Shannon May 14th–17th, 1998

Author

Sullivan, P. A., Murphy, D., Sullivan, P. A., Keogh, S., Sullivan, P. A., Nash, P., Kaarisalo, M. M., Marttila, J., Immonen-Raiha, P., Salomaa, V., Torppa, J., Tuomilehto, J., Siani, A., Racone, R., Ragone, E., Stinga, F., Strazzullol, P., Cappuccio, F. P., Trevisan, M., Farinaro, E., Mellone, C., Fox, K. F., Cowie, M. R., Wood, D. A., Coats, A. J., Poole Wilson, P. A., Sutton, G. C., Yarnell, J., Sweetnam, P., Thomas, H., Piwonski, J., Piotrowski, W., Pytlak, A., Wannamethee, S. G., Shaper, A. G., Walker, M., Sharpe, P. C., Young, I. S., Hasselwander, O., McMaster, D., Mercer, C., McGrath, L. T., Evans, A. E., Thomas, F., Guize, L., Ducimetiere, P., Benetos, A., Rosolova, H., Simon, J., Mayer, O., Sefrna, F., Mayer, O., Šimon, J., Rosolova, H., Racek, J., Trefil, L., Marin-Tarlea, M., Carp, C., Apetrei, E., Ginghina, C., Serban, I., Florica, N., Ceck, C., Patrascoiu, M., Ginghina, C., Carp, C., Apetrei, E., Tarlea, M., Cioranu, R., Florica, N., Ceck, C., Vaduva, M., Mihaescu, D., Lapadat, M., Ashton, W. D., Wood, D., Nanchahahal, K., Kelleher, C. C., Brennan, P. J., Howarth, D., Meade, T. W., Kelleher, C. C., Fallon, U. B., McCarthy, U., O’Donnell, M. M. K., Dineen, B., Jousilahti, P., Vartiainen, E., Tuomilehto, J., Puska, P., Kastarinen, M., Nissinen, A., Salomaa, V., Vartiainen, E., Jousilahti, P., Tuomilehto, J., Puska, P., Rosengren, A., Wedel, H., Wilhelmsen, L., Liese, A. D., Hense, H. W., Keil, U., Keil, U., Liese, A. D., Hense, H. W., Filipiak, B., Döring, A., Stieber, J., Lowel, H., De Laet, C., Brasseur, D., Kahn, A., Wautrecht, J. C., Decuyper, J., Boeynaems, J. M., Jousilahti, P., Vartiainen, E., Tuomilehto, J., Sundvall, J., Puska, P., Marques-Vidal, P., Ferrières, J., Haas, B., Evans, A., Amouyel, P., Luc, G., Ducimetiere, P., Marques-Vidal, P., Ferrieres, J., Arveiler, D., Montaye, M., Evans, A., Ducimetiere, P., Fuentes, R., Notkola, I. -L., Shemeikka, S., Tuomilehto, J., Nissinen, A., Mak, R., De BacquerBacquer, D., De Backer, G., Stam, M., Koyuncu, R., de Smet, P., Kornitzer, M., Braeckman, L., De Backer, G., De Bacquer, D., Claeys, L., Delanghe, J., De Bacquer, D., Kornitzer, M., De Backer, G., Cífkova, R., Pit’ha, J., Červenka, L., Šejda, T., Lanska, V., Škodová, Z., Stavek, P., Poledne, R., Cífková, R., Duskova, A., Hauserová, G., Hejl, Z., Lánská, V., Škodova, Z., Pistulková, H., Poledne, R., Hubáček, J., Pit’ha, J., Stávek, P., Lánská, V., Cífková, R., Faleiro, L. L., Rodrigues, D., Fonseca, A., Martins, M. C., Norris, R. M., Nyyssönen, K., Seppänen, K., Salonen, R., Kantola, M., Salonen, J. T., Parviainen, M. T., De Henauw, S., Myny, K., Doyen, Z., Van Oyen, H., Tafforeau, J., Kornitzer, M., De Backer, G., Benetos, A., Thomas, F., Guize, L., Immonen-Räihä, P., Kaarisalo, M., Marttila, R. J., Torppa, J., Tuomilehto, J., Houterman, S., Hofman, B., Witteman, J. C. M., Verschuren, W. M. M., van de Vijver, L. P. L., Kardinaal, A. F. M., Grobbee, D. E., van Poppel, G., Princen, H. M. G., Kornitzer, M., Doven, M., Koyuncu, R., De Bacquer, D., Myny, K., De Backer, G., Tafforeau, J., Van Oven, H., Doyen, M., Koyuncu, R., Kornitzer, M., De Bacquer, D., Myny, K., De Backer, G., Tafforeau, J., Van Oyen, H., de Bree, A., Verschuren, W. M. M., Blom, H. J., Mulder, I., Smit, H. A., Menotti, A., Kromhout, D., Van den Hoogen, P. C. W., Hofman, A., Witteman, J. C. M., Feskens, E. J. M., Štika, L., Bruthans, J., Wierzbicka, M., Bolinska, H., Voutilainen, S., Nyyssönen, K., Salonen, R., Lakka, T. A., Salonen, J. T., Lakka, H -M., Lakka, T. A., Salonen, J. T., Tuomainen, T-P., Nyyssonen, K., Salonen, J. T., Punnonen, K., Yarnell, J., Patterson, C., Thomas, H., Sweetnam, P., Smith, W. C. S., Campbell, S. E., Cardy, A., Phillips, D. O., Helms, P. J., Squair, J., Smith, W. C. S., Cardy, A., Phillips, D. O., Helms, P. J., Squair, J., Smith, W. C. S., Cardy, A., Phillips, D. O., Helms, P. J., Squair, J., Pytlak, A., Piotrowski, W., Rywik, S., Waskiewicz, A., Sygnowska, E., Szczesniewska, D., Sygnowska, E., Waskiewicz, A., Wagrowska, H., Polakowska, M., Rywik, S., Broda, G., Jasinski, B., Piotrowski, W., Elandt-Johnson, R. C., Wagrowska, H., Kupsé, W., Szczesniewska, D., Platonov, D. Y., Haapanen, N., Miilunpalo, S., Vuori, I., Pasanen, M., Oja, P., Urponen, H., Kopp, M. S., Skrabski, A., Szedmák, S., Boaz, M., Biro, A., Katzir, Z., Matas, T., Smetana, S., Green, M., Whincup, P. H., Morris, R., Walker, M., Lennon, L., Thomson, A., Ebrahim, S. J. B., Refsum, H., Ueland, P. M., Perry, I. J., Boer, J. M. A., Kuivenhoven, J. A., Feskens, E. J. M., Schouten, E. G., Havekes, L. M., Seidell, J. C., Kastelein, J. J. P., Kromhout, D., Oomen, C. M., Feskens, E. J. M., Rasanen, L., Nissinen, A., Fidanza, F., Menotti, A., Kok, F. J., Kromhout, D., Sileikiene, L., Klambienne, J., Milasauskiene, Z., Cappuccio, F. P., Siani, A., Barba, G., Russo, L., Ragone, E., Strazzullo, P., Farinaro, E., Trevisan, M., Schnohr, P., Parner, J., Lange, P., Meleady, R., Graham, I. M., Ueland, P. M., Refsum, H., Blom, H., Whitehead, A. S., Daly, L. E., Stefanovic, B., Boskovic, D., Mitrovic, P., Perunicic, J., Vukcevic, V., Radovanovic, N., Terzic, B., Mrdovic, I., Orilc, D., Matic, G., Vasiljevic, Z., Mitrovic, P., Boskovic, D., Stefanovic, B., Perunicic, J., Vukcevic, V., Mrdovic, I., Radovanovic, N., Orlic, D., Matic, G., Milentijevic, B., Rajic, D., Mitrovic, N., Boskovic, S., Vasiljevic, Z., Marin-Tarlea, M., Carp, C., Apetrei, E., Serban, I., Ceck, C., Patrascsoiu, M., Florica, N., Mihaescu, D., Murphy, C., Meleady, R., Ingram, S., Love, J., Graham, I., Graham, I. M., Meleady, R., van Berkel, T. F. M., Deckers, J. W., and De Bacquer, D.

Published
1998
Full Text
View/download PDF

25. Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality

Author

MARKLUND, M., WU, J. H. Y., IMAMURA, F., DEL GOBBO, L. C., FRETTS, A., DE GOEDE, J., Shi, P., TINTLE, N., WENNBERG, M., ASLIBEKYAN, S., CHEN, T. A., DE OLIVEIRA OTTO, M. C., Hirakawa, Y., ERIKSEN, H. H., KROGER, J., LAGUZZI, F., LANKINEN, M., Murphy, R. A., PREM, K., Samieri, C., Virtanen, J., WOOD, A. C., Wong, K., YANG, W. S., Zhou, X., BAYLIN, A., BOER, J. M. A., BROUWER, I. A., Campos, H., CHAVES, P. H. M., CHIEN, K. L., DE FAIRE, U., DJOUSSE, L., EIRIKSDOTTIR, G., EL-ABBADI, N., FOROUHI, N. G., MICHAEL GAZIANO, J., GELEIJNSE, J. M., GIGANTE, B., GILES, G., GUALLAR, E., GUDNASON, V., HARRIS, T., HARRIS, W. S., Helmer, Catherine, HELLENIUS, M. L., Hodge, A., Hu, F. B., JACQUES, P. F., JANSSON, J. H., Kalsbeek, A., Khaw, K. T., Koh, W. P., Laakso, M., LEANDER, K., LIN, H. J., LIND, L., LUBEN, R., Luo, J., MCKNIGHT, B., MURSU, J., Ninomiya, T., Overvad, K., PSATY, B. M., RIMM, E., SCHULZE, M. B., SISCOVICK, D., SKJELBO NIELSEN, M., SMITH, A. V., STEFFEN, B. T., STEFFEN, L., Sun, Q., SUNDSTROM, J., TSAI, M. Y., TUNSTALL-PEDOE, H., UUSITUPA, M. I. J., VAN DAM, R. M., VEENSTRA, J., MONIQUE VERSCHUREN, W. M., Wareham, N., WILLETT, W., Woodward, M., Yuan, J. M., Micha, R., LEMAITRE, R. N., Mozaffarian, D., Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, LEHA
Abstract

International audience; BACKGROUND: Global dietary recommendations for and cardiovascular effects of linoleic acid, the major dietary omega-6 fatty acid, and its major metabolite, arachidonic acid, remain controversial. To address this uncertainty and inform international recommendations, we evaluated how in vivo circulating and tissue levels of linoleic acid (LA) and arachidonic acid (AA) relate to incident cardiovascular disease (CVD) across multiple international studies. METHODS: We performed harmonized, de novo, individual-level analyses in a global consortium of 30 prospective observational studies from 13 countries. Multivariable-adjusted associations of circulating and adipose tissue LA and AA biomarkers with incident total CVD and subtypes (coronary heart disease (CHD), ischemic stroke, cardiovascular mortality) were investigated according to a prespecified analytical plan. Levels of LA and AA, measured as % of total fatty acids, were evaluated linearly according to their interquintile range (i.e., the range between the mid-point of the first and fifth quintiles), and categorically by quintiles. Study-specific results were pooled using inverse-variance weighted meta-analysis. Heterogeneity was explored by age, sex, race, diabetes, statin use, aspirin use, omega-3 levels, and fatty acid desaturase 1 genotype (when available). RESULTS: In 30 prospective studies with medians of follow-up ranging 2.5 to 31.9 years, 15,198 incident cardiovascular events occurred among 68,659 participants. Higher levels of LA were significantly associated with lower risks of total CVD, cardiovascular mortality, and ischemic stroke, with hazard ratios per interquintile range of 0.93 (95% CI: 0.88-0.99), 0.78 (0.70-0.85), and 0.88 (0.79-0.98), respectively, and nonsignificantly with lower CHD risk (0.94; 0.88-1.00). Relationships were similar for LA evaluated across quintiles. AA levels were not associated with higher risk of cardiovascular outcomes; comparing extreme quintiles, higher levels were associated with lower risk of total CVD (0.92; 0.86-0.99). No consistent heterogeneity by population subgroups was identified in the observed relationships. CONCLUSIONS: In pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention.

Published
2019
Full Text
View/download PDF

26. Substitution among milk and yogurt products and the risk of incident type 2 diabetes in the EPIC‐NL cohort.

Author

Stuber, J. M., Vissers, L. E. T., Verschuren, W. M. M., Boer, J. M. A., Schouw, Y. T., and Sluijs, I.

Subjects
CONFIDENCE intervals, LONGITUDINAL method, MILK, MULTIVARIATE analysis, TYPE 2 diabetes, RISK assessment, SELF-evaluation, YOGURT, DISEASE incidence, PROPORTIONAL hazards models, DESCRIPTIVE statistics, DISEASE risk factors
Abstract

Background: Higher dairy consumption has been associated with lower type 2 diabetes (T2D) risk, whereas dairy product subtypes appear to differ in their T2D risk association. We investigated whether replacing one type of milk or yogurt product with another is associated with T2D incidence. Methods: Participants of the European Prospective Investigation into Cancer and Nutrition‐Netherlands (EPIC‐NL) cohort (n = 35 982) were included in the present study. Information on milk and yogurt consumption at baseline was obtained by a validated food frequency questionnaire. T2D cases were identified by self‐report or linkage to the hospital discharge registry, and validated by consulting the general practitioner. Multivariable Cox proportional hazard models were used to estimate associations. Results: During a mean of 15 years of follow‐up, 1467 indecent T2D cases were validated. Median total milk and yogurt intake was 1.5 servings (25th percentile to 75th percentile: 0.8–2.4). After adjustment for demographic and cardiovascular risk factors, replacement of one serving (200 g) of whole‐fat milk [hazard ratio (HR) = 0.93, 95% confidence interval (CI) = 0.60–1.44], buttermilk (HR = 0.88, 95% CI = 0.58‐1.34), skimmed milk (HR = 0.87, 95% CI = 0.57–1.32) or skimmed fermented milk (HR = 0.99, 95% CI = 0.63–1.54) with whole‐fat yogurt was not associated with T2D risk. Substitutions among other milk and yogurt products were also not associated with T2D risk. Sensitivity analysis investigating T2D risk halfway follow‐up suggested a lower risk for substitutions with whole‐fat yogurt. Conclusions: No evidence was found for the association between substitutions among milk and yogurt products and the risk of incident T2D, although we cannot exclude possible attenuation of results as a result of dietary changes over time. This analysis should be repeated in a population with a wider consumption range of whole‐fat yogurt. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. 1149Development and validation of a decision-support tool for individualizing lifelong lipid, blood-pressure, and aspirin treatment in people without cardiovascular disease

Author

Jaspers, N E M, primary, Blaha, M J, additional, Matsushita, K, additional, Joeckel, K H, additional, Erbel, R A, additional, Visseren, F L J, additional, Van Der Graaf, Y, additional, Van Der Schouw, Y T, additional, Nambi, V, additional, Boer, J M A, additional, and Dorresteijn, J A N, additional

Published
2018
Full Text
View/download PDF

30. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., Den Boer, M. L., Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., and Den Boer, M. L.

Published
2018

31. Risk thresholds for alcohol consumption:combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies

Author

Wood, A. M. (Angela M.), Kaptoge, S. (Stephen), Butterworth, A. S. (Adam S.), Willeit, P. (Peter), Warnakula, S. (Samantha), Bolton, T. (Thomas), Paige, E. (Ellie), Paul, D. S. (Dirk S.), Sweeting, M. (Michael), Burgess, S. (Stephen), Bell, S. (Steven), Astle, W. (William), Stevens, D. (David), Koulman, A. (Albert), Selmer, R. M. (Randi M.), Verschuren, W. M. (W. M. Monique), Sato, S. (Shinichi), Njolstad, I. (Inger), Woodward, M. (Mark), Salomaa, V. (Veikko), Nordestgaard, B. G. (Borge G.), Yeap, B. B. (Bu B.), Fletcher, A. (Astrid), Melander, O. (Olle), Kuller, L. H. (Lewis H.), Balkau, B. (Beverley), Marmot, M. (Michael), Koenig, W. (Wolfgang), Casiglia, E. (Edoardo), Cooper, C. (Cyrus), Arndt, V. (Volker), Franco, O. H. (Oscar H.), Wennberg, P. (Patrik), Gallacher, J. (John), de la Camara, A. G. (Agustin Gomez), Volzke, H. (Henry), Dahm, C. C. (Christina C.), Dale, C. E. (Caroline E.), Bergmann, M. M. (Manuela M.), Crespo, C. J. (Carlos J.), van der Schouw, Y. T. (Yvonne T.), Kaaks, R. (Rudolf), Simons, L. A. (Leon A.), Lagiou, P. (Pagona), Schoufour, J. D. (Josje D.), Boer, J. M. (Jolanda M. A.), Key, T. J. (Timothy J.), Rodriguez, B. (Beatriz), Moreno-Iribas, C. (Conchi), Davidson, K. W. (Karina W.), Taylor, J. O. (James O.), Sacerdote, C. (Carlotta), Wallace, R. B. (Robert B.), Quiros, J. R. (J. Ramon), Tumino, R. (Rosario), Blazer, D. G. (Dan G., II), Linneberg, A. (Allan), Daimon, M. (Makoto), Panico, S. (Salvatore), Howard, B. (Barbara), Skeie, G. (Guri), Strandberg, T. (Timo), Weiderpass, E. (Elisabete), Nietert, P. J. (Paul J.), Psaty, B. M. (Bruce M.), Kromhout, D. (Daan), Salamanca-Fernandez, E. (Elena), Kiechl, S. (Stefan), Krumholz, H. M. (Harlan M.), Grioni, S. (Sara), Palli, D. (Domenico), Huerta, J. M. (Jose M.), Price, J. (Jackie), Sundstrom, J. (Johan), Arriola, L. (Larraitz), Arima, H. (Hisatomi), Travis, R. C. (Ruth C.), Panagiotakos, D. B. (Demosthenes B.), Karakatsani, A. (Anna), Trichopoulou, A. (Antonia), Kuhn, T. (Tilman), Grobbee, D. E. (Diederick E.), Barrett-Connor, E. (Elizabeth), van Schoor, N. (Natasja), Boeing, H. (Heiner), Overvad, K. (Kim), Kauhanen, J. (Jussi), Wareham, N. (Nick), Langenberg, C. (Claudia), Forouhi, N. (Nita), Wennberg, M. (Maria), Despres, J.-P. (Jean-Pierre), Cushman, M. (Mary), Cooper, J. A. (Jackie A.), Rodriguez, C. J. (Carlos J.), Sakurai, M. (Masaru), Shaw, J. E. (Jonathan E.), Knuiman, M. (Matthew), Voortman, T. (Trudy), Meisinger, C. (Christa), Tjonneland, A. (Anne), Brenner, H. (Hermann), Palmieri, L. (Luigi), Dallongeville, J. (Jean), Brunner, E. J. (Eric J.), Assmann, G. (Gerd), Trevisan, M. (Maurizio), Gillum, R. F. (Richard F.), Ford, I. (Ian), Sattar, N. (Naveed), Lazo, M. (Mariana), Thompson, S. G. (Simon G.), Ferrari, P. (Pietro), Leon, D. A. (David A.), Smith, G. D. (George Davey), Peto, R. (Richard), Jackson, R. (Rod), Banks, E. (Emily), Di Angelantonio, E. (Emanuele), Danesh, J. (John), Wood, A. M. (Angela M.), Kaptoge, S. (Stephen), Butterworth, A. S. (Adam S.), Willeit, P. (Peter), Warnakula, S. (Samantha), Bolton, T. (Thomas), Paige, E. (Ellie), Paul, D. S. (Dirk S.), Sweeting, M. (Michael), Burgess, S. (Stephen), Bell, S. (Steven), Astle, W. (William), Stevens, D. (David), Koulman, A. (Albert), Selmer, R. M. (Randi M.), Verschuren, W. M. (W. M. Monique), Sato, S. (Shinichi), Njolstad, I. (Inger), Woodward, M. (Mark), Salomaa, V. (Veikko), Nordestgaard, B. G. (Borge G.), Yeap, B. B. (Bu B.), Fletcher, A. (Astrid), Melander, O. (Olle), Kuller, L. H. (Lewis H.), Balkau, B. (Beverley), Marmot, M. (Michael), Koenig, W. (Wolfgang), Casiglia, E. (Edoardo), Cooper, C. (Cyrus), Arndt, V. (Volker), Franco, O. H. (Oscar H.), Wennberg, P. (Patrik), Gallacher, J. (John), de la Camara, A. G. (Agustin Gomez), Volzke, H. (Henry), Dahm, C. C. (Christina C.), Dale, C. E. (Caroline E.), Bergmann, M. M. (Manuela M.), Crespo, C. J. (Carlos J.), van der Schouw, Y. T. (Yvonne T.), Kaaks, R. (Rudolf), Simons, L. A. (Leon A.), Lagiou, P. (Pagona), Schoufour, J. D. (Josje D.), Boer, J. M. (Jolanda M. A.), Key, T. J. (Timothy J.), Rodriguez, B. (Beatriz), Moreno-Iribas, C. (Conchi), Davidson, K. W. (Karina W.), Taylor, J. O. (James O.), Sacerdote, C. (Carlotta), Wallace, R. B. (Robert B.), Quiros, J. R. (J. Ramon), Tumino, R. (Rosario), Blazer, D. G. (Dan G., II), Linneberg, A. (Allan), Daimon, M. (Makoto), Panico, S. (Salvatore), Howard, B. (Barbara), Skeie, G. (Guri), Strandberg, T. (Timo), Weiderpass, E. (Elisabete), Nietert, P. J. (Paul J.), Psaty, B. M. (Bruce M.), Kromhout, D. (Daan), Salamanca-Fernandez, E. (Elena), Kiechl, S. (Stefan), Krumholz, H. M. (Harlan M.), Grioni, S. (Sara), Palli, D. (Domenico), Huerta, J. M. (Jose M.), Price, J. (Jackie), Sundstrom, J. (Johan), Arriola, L. (Larraitz), Arima, H. (Hisatomi), Travis, R. C. (Ruth C.), Panagiotakos, D. B. (Demosthenes B.), Karakatsani, A. (Anna), Trichopoulou, A. (Antonia), Kuhn, T. (Tilman), Grobbee, D. E. (Diederick E.), Barrett-Connor, E. (Elizabeth), van Schoor, N. (Natasja), Boeing, H. (Heiner), Overvad, K. (Kim), Kauhanen, J. (Jussi), Wareham, N. (Nick), Langenberg, C. (Claudia), Forouhi, N. (Nita), Wennberg, M. (Maria), Despres, J.-P. (Jean-Pierre), Cushman, M. (Mary), Cooper, J. A. (Jackie A.), Rodriguez, C. J. (Carlos J.), Sakurai, M. (Masaru), Shaw, J. E. (Jonathan E.), Knuiman, M. (Matthew), Voortman, T. (Trudy), Meisinger, C. (Christa), Tjonneland, A. (Anne), Brenner, H. (Hermann), Palmieri, L. (Luigi), Dallongeville, J. (Jean), Brunner, E. J. (Eric J.), Assmann, G. (Gerd), Trevisan, M. (Maurizio), Gillum, R. F. (Richard F.), Ford, I. (Ian), Sattar, N. (Naveed), Lazo, M. (Mariana), Thompson, S. G. (Simon G.), Ferrari, P. (Pietro), Leon, D. A. (David A.), Smith, G. D. (George Davey), Peto, R. (Richard), Jackson, R. (Rod), Banks, E. (Emily), Di Angelantonio, E. (Emanuele), and Danesh, J. (John)

Abstract

Background: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. Methods: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose–response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th–95th percentile 1·04–13·5]) from 71 011 participants from 37 studies. Findings: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality ris

Published
2018

32. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Lab Reumatologie/Klinische Immunologie, Other research (not in main researchprogram), PMC Medisch specialisten, CMM, Genetica Sectie Genoomdiagnostiek, Child Health, Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., Den Boer, M. L., Lab Reumatologie/Klinische Immunologie, Other research (not in main researchprogram), PMC Medisch specialisten, CMM, Genetica Sectie Genoomdiagnostiek, Child Health, Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., and Den Boer, M. L.

Published
2018

33. Overweight duration in older adults and cancer risk: a study of cohorts in Europe and the United States

Author

Arnold, M., Freisling, H., Stolzenberg-Solomon, R., Kee, F., O’Doherty, M. G., Ordóñez-Mena, J. M., Wilsgaard, T., May, A. M., Bueno-de-Mesquita, H. B., Tjønneland, A., Orfanos, P., Trichopoulou, A., Boffetta, P., Bray, F., Jenab, M., Soerjomataram, I., Baceviciene, M., Boer, J. M. A., Drygas, W., Eriksson, S., Feskens, E., Gafarov, V., Gardiner, J., Hakansson, N., Jansson, J. -H., Jousilahti, P., Kampman, E., Kontto, J., Kubinova, R., Leenders, M., Linneberg, A., Lochen, M. -L., Lorbeer, R., Malyutina, S., Mathiesen, E. B., Melhus, H., Michaëlsson, K., Njolstad, I., Orsini, N., Pajak, A., Pikhart, H., Pisinger, C., Salomaa, V., Sánchez, M. -J., Sans, S., Schaan, B., Schneider, A., Siganos, G., Söderberg, S., Streppel, M., Tamošiunas, A., Veronesi, G., Waterham, E., Wennberg, P., on behalf of the CHANCES consortium, Arnold, M., Freisling, H., Stolzenberg-Solomon, R., Kee, F., O’Doherty, M.G., Ordóñez-Mena, J.M., Wilsgaard, T., May, A.M., Bueno-de-Mesquita, H.B., Tjønneland, A., Orfanos, P., Trichopoulou, A., Boffetta, P., Bray, F., Jenab, M., Soerjomataram, I., Baceviciene, M., Boer, J.M.A., Drygas, W., Eriksson, S., Feskens, E., Gafarov, V., Gardiner, J., Hakansson, N., Jansson, J.-H., Jousilahti, P., Kampman, E., Kontto, J., Kubinova, R., Leenders, M., Linneberg, A., Lochen, M.-L., Lorbeer, R., Malyutina, S., Mathiesen, E.B., Melhus, H., Michaëlsson, K., Njolstad, I., Orsini, N., Pajak, A., Pikhart, H., Pisinger, C., Salomaa, V., Sánchez, M.-J., Sans, S., Schaan, B., Schneider, A., Siganos, G., Söderberg, S., Streppel, M., Tamošiunas, A., Veronesi, G., Waterham, E., Wennberg, P., and on behalf of the CHANCES consortium

Subjects
Gerontology, Male, Time Factors, Epidemiology, Overweight, Body Mass Index, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Risk Factors, Neoplasms, 030212 general & internal medicine, Cancer, 2. Zero hunger, Overweight and cancer risk, Hazard ratio, Smoking, Cohort, Confounding Factors, Epidemiologic, Middle Aged, 3. Good health, Europe, 030220 oncology & carcinogenesis, Female, medicine.symptom, Cohort study, Hormone Replacement Therapy, Article, Diabetes Complications, 03 medical and health sciences, Breast cancer, Sex Factors, SDG 3 - Good Health and Well-being, Journal Article, medicine, Humans, Obesity, CHANCES, VLAG, Aged, Proportional Hazards Models, Global Nutrition, Wereldvoeding, Cancer prevention, Epidemiologic, business.industry, Prevention, medicine.disease, Confounding Factors, United States, Ageing, business, Body mass index, Demography
Abstract

Recent studies have shown that cancer risk related to overweight and obesity is mediated by time and might be better approximated by using life years lived with excess weight. In this study we aimed to assess the impact of overweight duration and intensity in older adults on the risk of developing different forms of cancer. Study participants from seven European and one US cohort study with two or more weight assessments during follow-up were included (n = 329,576). Trajectories of body mass index (BMI) across ages were estimated using a quadratic growth model; overweight duration (BMI = 25) and cumulative weighted overweight years were calculated. In multivariate Cox models and random effects analyses, a longer duration of overweight was significantly associated with the incidence of obesity-related cancer [overall hazard ratio (HR) per 10-year increment: 1.36; 95 % CI 1.12–1.60], but also increased the risk of postmenopausal breast and colorectal cancer. Additionally accounting for the degree of overweight further increased the risk of obesity-related cancer. Risks associated with a longer overweight duration were higher in men than in women and were attenuated by smoking. For postmenopausal breast cancer, increased risks were confined to women who never used hormone therapy. Overall, 8.4 % of all obesity-related cancers could be attributed to overweight at any age. These findings provide further insights into the role of overweight duration in the etiology of cancer and indicate that weight control is relevant at all ages. This knowledge is vital for the development of effective and targeted cancer prevention strategies. © 2016, Springer Science+Business Media Dordrecht.

Published
2016
Full Text
View/download PDF

34. Meal patterns across ten European countries - results from the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study

Author

Huseinovic, E. Winkvist, A. Slimani, N. Park, M. K. and Freisling, H. Boeing, H. Buckland, G. Schwingshackl, L. and Weiderpass, E. Rostgaard-Hansen, A. L. Tjonneland, A. and Affret, A. Boutron-Ruault, M. C. Fagherazzi, G. Katzke, V. and Kuehn, T. Naska, A. Orfanos, P. Trichopoulou, A. and Pala, V. Palli, D. Ricceri, F. de Magistris, M. Santucci and Tumino, R. Engeset, D. Enget, T. Skeie, G. Barricarte, A. Bonet, C. B. Chirlaque, M. D. Amiano, P. Quiros, J. R. Sanchez, M. J. Dias, J. A. Drake, I. Wennberg, M. and Boer, J. M. A. Ocke, M. C. Verschuren, W. M. M. Lassale, C. and Perez-Cornago, A. Riboli, E. Ward, H. Forslund, H. Berteus

Abstract

Objective: To characterize meal patterns across ten European countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study. Design: Cross-sectional study utilizing dietary data collected through a standardized 24 h diet recall during 1995-2000. Eleven predefined intake occasions across a 24 h period were assessed during the interview. In the present descriptive report, meal patterns were analysed in terms of daily number of intake occasions, the proportion reporting each intake occasion and the energy contributions from each intake occasion. Setting: Twenty-seven centres across ten European countries. Subjects: Women (64 %) and men (36 %) aged 35-74 years (n 36 020). Results: Pronounced differences in meal patterns emerged both across centres within the same country and across different countries, with a trend for fewer intake occasions per day in Mediterranean countries compared with central and northern Europe. Differences were also found for daily energy intake provided by lunch, with 38-43% for women and 41-45% for men within Mediterranean countries compared with 16-27% for women and 20-26% for men in central and northern European countries. Likewise, a south-north gradient was found for daily energy intake from snacks, with 13-20% (women) and 10-17% (men) in Mediterranean countries compared with 24-34% (women) and 23-35% (men) in central/northern Europe. Conclusions: We found distinct differences in meal patterns with marked diversity for intake frequency and lunch and snack consumption between Mediterranean and central/northern European countries. Monitoring of meal patterns across various cultures and populations could provide critical context to the research efforts to characterize relationships between dietary intake and health.

Published
2016

35. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Jerchel, I S, primary, Hoogkamer, A Q, additional, Ariës, I M, additional, Steeghs, E M P, additional, Boer, J M, additional, Besselink, N J M, additional, Boeree, A, additional, van de Ven, C, additional, de Groot-Kruseman, H A, additional, de Haas, V, additional, Horstmann, M A, additional, Escherich, G, additional, Zwaan, C M, additional, Cuppen, E, additional, Koudijs, M J, additional, Pieters, R, additional, and den Boer, M L, additional

Published
2017
Full Text
View/download PDF

37. Fluidity of the dietary fatty acid profile and risk of coronary heart disease and ischemic stroke: Results from the EPIC-Netherlands cohort study

Author

Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Epi Hart- en Vaatziekten Team 2, Public Health Epidemiologie, Cardiovasculaire Epidemiologie, Sluijs, I, Praagman, J, Boer, J M A, Verschuren, W M M, van der Schouw, Y T, Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Epi Hart- en Vaatziekten Team 2, Public Health Epidemiologie, Cardiovasculaire Epidemiologie, Sluijs, I, Praagman, J, Boer, J M A, Verschuren, W M M, and van der Schouw, Y T

Published
2017

38. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: Meta-analysis of Individual participant data from prospective cohort studies of the CHANCES consortium

Author

Mons, U., Müezzinler, A., Gellert, C., Schöttker, B., Abnet, C. C., Bobak, M., De Groot, L., Freedman, N. D., Jansen, E., Kee, F., Kromhout, D., Kuulasmaa, K., Tiina, L., O'Doherty, M. G., Bas, B. -D. -M., Orfanos, P., Peters, A., Van Der Schouw, Y. T., Wilsgaard, T., Wolk, A., Trichopoulou, A., Boffetta, P., Brenner, H., Baceviciene, M., Boer, J. M. A., Drygas, W., Eriksson, S., Feskens, E., Gafarov, V., Gardiner, J., Håkansson, N., Jansson, J. -H., Jousilahti, P., Kampman, E., Kontto, J., Kubinova, R., Leenders, M., Linneberg, A., Løchen, M. -L., Lorbeer, R., Malyutina, S., Mathiesen, E. B., Melhus, H., Michaëlsson, K., Njølstad, I., Orsini, N., Pajak, A., Pikhart, H., Pisinger, C., Salomaa, V., Sánchez, M. -J., Sans, S., Schaan, B., Schneider, A., Siganos, G., Söderberg, S., Streppel, M., Tamošiunas, A., Veronesi, G., Waterham, E., Wennberg, P., Mons, U., Müezzinler, A., Gellert, C., Schöttker, B., Abnet, C.C., Bobak, M., De Groot, L., Freedman, N.D., Jansen, E., Kee, F., Kromhout, D., Kuulasmaa, K., Tiina, L., O'Doherty, M.G., Bas, B.-D.-M., Orfanos, P., Peters, A., Van Der Schouw, Y.T., Wilsgaard, T., Wolk, A., Trichopoulou, A., Boffetta, P., Brenner, H., Baceviciene, M., Boer, J.M.A., Drygas, W., Eriksson, S., Feskens, E., Gafarov, V., Gardiner, J., Håkansson, N., Jansson, J.-H., Jousilahti, P., Kampman, E., Kontto, J., Kubinova, R., Leenders, M., Linneberg, A., Løchen, M.-L., Lorbeer, R., Malyutina, S., Mathiesen, E.B., Melhus, H., Michaëlsson, K., Njølstad, I., Orsini, N., Pajak, A., Pikhart, H., Pisinger, C., Salomaa, V., Sánchez, M.-J., Sans, S., Schaan, B., Schneider, A., Siganos, G., Söderberg, S., Streppel, M., Tamošiunas, A., Veronesi, G., Waterham, E., and Wennberg, P.

Subjects
Medicine (all), Smoking - cardiovascular mortality - stroke
Abstract

OBJECTIVE: To investigate the impact of smoking and smoking cessation on cardiovascular mortality, acute coronary events, and stroke events in people aged 60 and older, and to calculate and report risk advancement periods for cardiovascular mortality in addition to traditional epidemiological relative risk measures. DESIGN: Individual participant meta-analysis using data from 25 cohorts participating in the CHANCES consortium. Data were harmonised, analysed separately employing Cox proportional hazard regression models, and combined by meta-analysis. RESULTS: Overall, 503 905 participants aged 60 and older were included in this study, of whom 37 952 died from cardiovascular disease. Random effects meta-analysis of the association of smoking status with cardiovascular mortality yielded a summary hazard ratio of 2.07 (95% CI 1.82 to 2.36) for current smokers and 1.37 (1.25 to 1.49) for former smokers compared with never smokers. Corresponding summary estimates for risk advancement periods were 5.50 years (4.25 to 6.75) for current smokers and 2.16 years (1.38 to 2.39) for former smokers. The excess risk in smokers increased with cigarette consumption in a dose-response manner, and decreased continuously with time since smoking cessation in former smokers. Relative risk estimates for acute coronary events and for stroke events were somewhat lower than for cardiovascular mortality, but patterns were similar. CONCLUSIONS: Our study corroborates and expands evidence from previous studies in showing that smoking is a strong independent risk factor of cardiovascular events and mortality even at older age, advancing cardiovascular mortality by more than five years, and demonstrating that smoking cessation in these age groups is still beneficial in reducing the excess risk. © 2015 BMJ Publishing Group Ltd.

Published
2015

39. Meal patterns across ten European countries : results from the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study

Author

Huseinovic, E., Winkvist, A., Slimani, N., Park, M. K., Freisling, H., Boeing, H., Buckland, G., Schwingshackl, L., Weiderpass, E., Rostgaard-Hansen, A. L., Tjønneland, A., Affret, A., Boutron-Ruault, M. C., Fagherazzi, G., Katzke, V., Kühn, T., Naska, A., Orfanos, P., Trichopoulou, A., Pala, V., Palli, D., Ricceri, F., Santucci de Magistris, M., Tumino, R., Engeset, D., Enget, T., Skeie, G., Barricarte, A., Bonet, C. B., Chirlaque, M. D., Amiano, P., Quirós, J. R., Sánchez, M. J., Dias, J. A., Drake, I., Wennberg, Maria, Boer, J. M. A., Ocké, M. C., Verschuren, W. M. M., Lassale, C., Perez-Cornago, A., Riboli, E., Ward, H., Bertéus Forslund, H., Huseinovic, E., Winkvist, A., Slimani, N., Park, M. K., Freisling, H., Boeing, H., Buckland, G., Schwingshackl, L., Weiderpass, E., Rostgaard-Hansen, A. L., Tjønneland, A., Affret, A., Boutron-Ruault, M. C., Fagherazzi, G., Katzke, V., Kühn, T., Naska, A., Orfanos, P., Trichopoulou, A., Pala, V., Palli, D., Ricceri, F., Santucci de Magistris, M., Tumino, R., Engeset, D., Enget, T., Skeie, G., Barricarte, A., Bonet, C. B., Chirlaque, M. D., Amiano, P., Quirós, J. R., Sánchez, M. J., Dias, J. A., Drake, I., Wennberg, Maria, Boer, J. M. A., Ocké, M. C., Verschuren, W. M. M., Lassale, C., Perez-Cornago, A., Riboli, E., Ward, H., and Bertéus Forslund, H.

Abstract

OBJECTIVE: To characterize meal patterns across ten European countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study. DESIGN: Cross-sectional study utilizing dietary data collected through a standardized 24 h diet recall during 1995-2000. Eleven predefined intake occasions across a 24 h period were assessed during the interview. In the present descriptive report, meal patterns were analysed in terms of daily number of intake occasions, the proportion reporting each intake occasion and the energy contributions from each intake occasion. SETTING: Twenty-seven centres across ten European countries. SUBJECTS: Women (64 %) and men (36 %) aged 35-74 years (n 36 020). RESULTS: Pronounced differences in meal patterns emerged both across centres within the same country and across different countries, with a trend for fewer intake occasions per day in Mediterranean countries compared with central and northern Europe. Differences were also found for daily energy intake provided by lunch, with 38-43 % for women and 41-45 % for men within Mediterranean countries compared with 16-27 % for women and 20-26 % for men in central and northern European countries. Likewise, a south-north gradient was found for daily energy intake from snacks, with 13-20 % (women) and 10-17 % (men) in Mediterranean countries compared with 24-34 % (women) and 23-35 % (men) in central/northern Europe. CONCLUSIONS: We found distinct differences in meal patterns with marked diversity for intake frequency and lunch and snack consumption between Mediterranean and central/northern European countries. Monitoring of meal patterns across various cultures and populations could provide critical context to the research efforts to characterize relationships between dietary intake and health.

Published
2016
Full Text
View/download PDF

40. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals

Author

Guo, Y., Lanktree, M. B., Taylor, K. C., Hakonarson, H., Lange, L. A., Keating, B. J., Fairfax, B. P., Elbers, C. C., Barnard, J., Farrall, M., Padmanabhan, S., Baumert, J., Castillo, B. A., Gaunt, T. R., Gong, Y., Rajagopalan, R., Romaine, S. P., Kumari, M., Rafelt, S., Smith, E. N., Li, Y. R., Sivapalaratnam, S., van Iperen, E. P., Speliotes, E. K., Toskala, E., Zhang, L., Ochs-Balcom, H. M., Bhangale, T. R., Chandrupatla, H. R., Drenos, F., Gieger, C., Gupta, J., Johnson, T., Kleber, M. E., Makino, S., Mangino, M., Meng, Y., Nelson, C. P., Pankow, J. S., Pankratz, N., Price, T. S., Shaffer, J., Shen, H., Tischfield, S., Tomaszewski, M., Atwood, L. D., Bailey, K. M., Balasubramanyam, A., Baldwin, C. T., Basart, H., Bauer, F., Behr, E. R., Beitelshees, A. L., Berenson, G. S., Beresford, S. A., Bezzina, C. R., Bhatt, D. L., Boer, J. M., Braund, P. S., Burke, G. L., Burkley, B., Carty, C., Chen, W., Clarke, R., Cooper-DeHoff, R. M., Curtis, S. P., de Bakker, P. I., de Jong, J. S., Delles, C., Dominiczak, A. F., Duggan, D., Feldman, H. I., Furlong, C. E., Gorski, M. M., Gums, J. G., Hardwick, R., Hastie, C., Heid, I. M., Huang, G.-H., Huggins, G. S., Humphries, S. E., Kirkland, S. A., Kivimaki, M., Klein, R., Klein, B. E., Knowler, W. C., Kottke-Marchant, K., LaCroix, A. Z., Langaee, T. Y., Li, M., Lyon, H. N., Maiwald, S., Marshall, J. K., Mehta, A., Meijs, M. F., Melander, O., Meyer, N., Mitra, N., Molony, C. M., Morrow, D. A., Murugesan, G., Newhouse, S. J., Nieto, J. F., Onland-Moret, N. C., Ouwehand, W. H., Palmen, J., Pepine, C. J., Ranchalis, J., Rosas, S. E., Rosenthal, E. A., Scharnagl, H., Schork, N. J., Schreiner, P. J., Shah, T., Shashaty, M., Shimbo, D., Srinivasan, S. R., Thomas, F., Tobin, M. D., Tsai, M. Y., Verschuren, W. M. M., Wagenknecht, L. E., Winkelmann, B. R., Young, T., Yusuf, S., Zafarmand, M. H., Zmuda, J. M., Zwinderman, A. H., Anand, S. S., Balmforth, A. J., Boehm, B. O., Boerwinkle, E., Burton, P. R., Cappola, T. P., Casas, J. P., Caulfield, M. J., Christiani, D. C., Christie, J., Cruickshanks, K. J., Davey-Smith, G., Davidson, K. W., Day, I. N., Doevendans, P. A., Dorn, G. W., FitzGerald, G. A., Hall, A. S., Hingorani, A. D., Hirschhorn, J. N., Hofker, M. H., Hovingh, K. G., Illig, T., Jamshidi, Y., Jarvik, G. P., Johnson, J. A., Kanetsky, P. A., Kastelein, J. J., Koenig, W., Lawlor, D. A., Marz, W., McCaffery, J., Mega, J. L., Mitchell, B. D., Murray, S. S., O'Connell, J. R., Patel, S. R., Peters, A., Pettinger, M., Rader, D. J., Redline, S., Reilly, M. P., Sabatine, M. S., Schadt, E. E., Shuldiner, A. R., Silverstein, R. L., Spector, T. D., Taylor, H. A., Thorand, B., Trip, M. D., Watkins, H., Wichmann, H.- E., Fox, C. S., Grant, S. F., Peter, I., Talmud, P. J., Munroe, P. B., Wilson, J. G., Knight, J. C., Samani, N. J., Hegele, R. A., Asselbergs, F. W., Monda, K. L., van der Schouw, Y. T., Demerath, E. W., Wijmenga, C., Timpson, N. J., Reiner, A. P., North, K. E., Papanicolaou, G. J., Lange , L. A., Keating , B. J., Vascular Medicine, Amsterdam Public Health, Epidemiology and Data Science, Graduate School, Other departments, Amsterdam Cardiovascular Sciences, Cardiology, Other Research, and Public and occupational health

Subjects
Population, Single-nucleotide polymorphism, Genome-wide association study, Biology, Polymorphism, Single Nucleotide, Body Mass Index, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, SH2B1, Genotype, Ethnicity, Genetics, Humans, education, Molecular Biology, Gene, Genetics (clinical), 030304 developmental biology, Genetic association, 0303 health sciences, education.field_of_study, Association Studies Articles, General Medicine, Melanocortin 4 receptor, 030217 neurology & neurosurgery
Abstract

Recent genetic association studies have made progress in uncovering components of the genetic architecture of the body mass index (BMI). We used the ITMAT-Broad-Candidate Gene Association Resource (CARe) (IBC) array comprising up to 49 320 single nucleotide polymorphisms (SNPs) across ~2100 metabolic and cardiovascular-related loci to genotype up to 108 912 individuals of European ancestry (EA), African-Americans, Hispanics and East Asians, from 46 studies, to provide additional insight into SNPs underpinning BMI. We used a five-phase study design: Phase I focused on meta-analysis of EA studies providing individual level genotype data; Phase II performed a replication of cohorts providing summary level EA data; Phase III meta-analyzed results from the first two phases; associated SNPs from Phase III were used for replication in Phase IV; finally in Phase V, a multi-ethnic meta-analysis of all samples from four ethnicities was performed. At an array-wide significance (P < 2.40E-06), we identify novel BMI associations in loci translocase of outer mitochondrial membrane 40 homolog (yeast) - apolipoprotein E - apolipoprotein C-I (TOMM40-APOE-APOC1) (rs2075650, P = 2.95E-10), sterol regulatory element binding transcription factor 2 (SREBF2, rs5996074, P = 9.43E-07) and neurotrophic tyrosine kinase, receptor, type 2 [NTRK2, a brain-derived neurotrophic factor (BDNF) receptor gene, rs1211166, P = 1.04E-06] in the Phase IV meta-analysis. Of 10 loci with previous evidence for BMI association represented on the IBC array, eight were replicated, with the remaining two showing nominal significance. Conditional analyses revealed two independent BMI-associated signals in BDNF and melanocortin 4 receptor (MC4R) regions. Of the 11 array-wide significant SNPs, three are associated with gene expression levels in both primary B-cells and monocytes; with rs4788099 in SH2B adaptor protein 1 (SH2B1) notably being associated with the expression of multiple genes in cis. These multi-ethnic meta-analyses expand our knowledge of BMI genetics.

Published
2013

42. Tailoring the Implementation of New Biomarkers Based on Their Added Predictive Value in Subgroups of Individuals

Author

HTA Onderzoek Team 1, Julius Centrum, Infection & Immunity, JC onderzoeksprogramma Methodologie, Cancer, Healthcare Innovation & Evaluation, Public Health Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, van Giessen, Anoukh, Moons, K. (Carl) G.M., de Wit, Ardine (G.A.), Verschuren, W. M. M., Boer, J. M. A., Koffijberg, H, HTA Onderzoek Team 1, Julius Centrum, Infection & Immunity, JC onderzoeksprogramma Methodologie, Cancer, Healthcare Innovation & Evaluation, Public Health Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, van Giessen, Anoukh, Moons, K. (Carl) G.M., de Wit, Ardine (G.A.), Verschuren, W. M. M., Boer, J. M. A., and Koffijberg, H

Published
2015

43. Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities

Author

van der Linden, M. H., primary, Boer, J. M., additional, Schneider, P., additional, Willekes, M., additional, Seslija, L., additional, De Lorenzo, P., additional, Valsecchi, M. G., additional, Cazzaniga, G., additional, Biondi, A., additional, den Boer, M. L., additional, Pieters, R., additional, and Stam, R. W., additional

Published
2015
Full Text
View/download PDF

44. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

Author

Boer, J M, primary, van der Veer, A, additional, Rizopoulos, D, additional, Fiocco, M, additional, Sonneveld, E, additional, de Groot-Kruseman, H A, additional, Kuiper, R P, additional, Hoogerbrugge, P, additional, Horstmann, M, additional, Zaliova, M, additional, Palmi, C, additional, Trka, J, additional, Fronkova, E, additional, Emerenciano, M, additional, do Socorro Pombo-de-Oliveira, M, additional, Mlynarski, W, additional, Szczepanski, T, additional, Nebral, K, additional, Attarbaschi, A, additional, Venn, N, additional, Sutton, R, additional, Schwab, C J, additional, Enshaei, A, additional, Vora, A, additional, Stanulla, M, additional, Schrappe, M, additional, Cazzaniga, G, additional, Conter, V, additional, Zimmermann, M, additional, Moorman, A V, additional, Pieters, R, additional, and den Boer, M L, additional

Published
2015
Full Text
View/download PDF

47. Eating out of home: energy, macro- and micronutrient intakes in 10 European countries. The European Prospective Investigation into Cancer and Nutrition

Author

Orfanos, P. Naska, A. Trichopoulou, A. Grioni, S. Boer, J. M. A. van Bakel, M. M. E. Ericson, U. Rohrmann, S. and Boeing, H. Rodriguez, L. Ardanaz, E. Sacerdote, C. and Giurdanella, M. C. Niekerk, E. M. Peeters, P. H. M. Manjer, J. van Guelpen, B. Deharveng, G. Skeie, G. Engeset, D. and Halkjaer, J. Jensen, A. M. McTaggart, A. Crowe, F. and Stratigakou, V. Oikonomou, E. Touvier, M. Niravong, M. and Riboli, E. Bingham, S. Slimani, N.

Abstract

Objectives: To assess the contribution of out-of-home (OH) energy and nutrient intake to total dietary intake, and to compare out-versus in-home nutrient patterns among 27 centres in 10 countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Methods: Between 1995 and 2000, 36 034 participants aged between 35-74 years completed a standardized 24-h dietary recall using a software programme (EPIC-Soft) that recorded the place of food/drink consumption. Eating OH was defined as the consumption of foods and beverages anywhere other than in household premises, irrespective of the place of purchase/preparation. Nutrient intakes were estimated using a standardized nutrient database. Mean intakes were adjusted for age and weighted by season and day of recall. Results: Among women, OH eating contributed more to total fat intake than to intakes of protein and carbohydrates. Among both genders, and particularly in southern Europe, OH eating contributed more to sugar and starch intakes and less to total fibre intake. The contribution of OH eating was also lower for calcium and vitamin C intakes. The composition of diet at home was different from that consumed out of home in southern countries, but was relatively similar in the north. Conclusions: In northern Europe, OH and in-home eating are homogeneous, whereas southern Europeans consider OH eating as a distinctive occasion. In most centres, women selected more fat-rich items when eating out. European Journal of Clinical Nutrition (2009) 63, S239-S262; doi: 10.1038/ejcn.2009.84

Published
2009

50. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Jerchel, I S, Hoogkamer, A Q, Ariës, I M, Steeghs, E M P, Boer, J M, Besselink, N J M, Boeree, A, van de Ven, C, de Groot-Kruseman, H A, de Haas, V, Horstmann, M A, Escherich, G, Zwaan, C M, Cuppen, E, Koudijs, M J, Pieters, R, and den Boer, M L

Abstract

RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defined subgroups using highly sensitive and quantitative methods are lacking. Targeted deep sequencing of 13 RAS pathway genes was performed in 461 pediatric BCP-ALL cases at initial diagnosis and in 19 diagnosis-relapse pairs. Mutations were present in 44.2% of patients, with 24.1% carrying a clonal mutation. Mutation frequencies were highest in high hyperdiploid, infant t(4;11)-rearranged, BCR-ABL1-like and B-other cases (50–70%), whereas mutations were less frequent in ETV6-RUNX1-rearranged, and rare in TCF3-PBX1- and BCR-ABL1-rearranged cases (27–4%). RAS pathway-mutated cells were more resistant to prednisolone and vincristine ex vivo. Clonal, but not subclonal, mutations were linked to unfavorable outcome in standard- and high-risk-treated patients. At relapse, most RAS pathway mutations were clonal (9 of 10). RAS mutant cells were sensitive to the MEK inhibitor trametinib ex vivo, and trametinib sensitized resistant cells to prednisolone. We conclude that RAS pathway mutations are frequent, and that clonal, but not subclonal, mutations are associated with unfavorable risk parameters in newly diagnosed pediatric BCP-ALL. These mutations may designate patients eligible for MEK inhibitor treatment.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results